Antitumor agent-79
Antitumor agent-79 shows good antiproliferative activities against hepatocellular carcinoma and breast cancer cells with IC50 values of 0.7-7.9 μM. Antitumor agent-79 induces cancer cells apoptosis and shows in vivo antitumor effects. Antitumor agent-79 can be used for the research of cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 2750233-50-0
- Formule: C23H19ClN2O
- Masse moléculaire:374.86
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
IC50 & Target
IC50: 0.7 μM (Huh7), 1.4 μM (HepG2), 1.5 μM (SNU475), 7.9 μM (Hep3B), 2.4 μM (FOCUS), 5.2 μM (Hep40), 6.5 μM (PLC-PRF-5), 3.7 μM (Mahlavu), 0.9 μM (MCF7), 0.9 μM (MDA-MB231), 1.0 μM (MDA-MB468), 1.8 μM (SKBR3), 5.5 μM (ZR75), 7.6 μM (MCF10A)[1]
In Vitro
Antitumor agent-79 (0.15-40 μM; 72 h) shows in vitro growth inhibitory activities against hepatocellular carcinoma and breast cancer cells with IC50 values of 0.7-7.9 μM[1]. Antitumor agent-79 (5 μM; 48 h) induces cell apoptosis by increasing the PARP cleavage[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Huh7, HepG2, SNU475, Hep3B, FOCUS, Hep40, PLC-PRF-5, Mahlavu, MCF7, MDA-MB231. MDA-MB468, SKBR3, ZR75 and MCF10A cell lines
-
Concentration:0.15-40 μM
-
Incubation Time:72 hours
-
Result:Time and dose-dependent showed cytotoxicity to hepatocellular carcinoma and breast cancer cells with IC50 values of 0.7, 1.4, 1.5, 7.9, 2.4, 5.2, 6.5, 3.7, 0.9, 0.9, 1.0, 1.8, 5.5 and 7.6 μM for Huh7, HepG2, SNU475, Hep3B, FOCUS, Hep40, PLC-PRF-5, Mahlavu, MCF7, MDA-MB231, MDA-MB468, SKBR3, ZR75 and MCF10A cells, respectively.
-
Cell Line:Mahlavu, Huh7, MCF-7 and MDA-MB-231 cancer cells
-
Concentration:5 μM
-
Incubation Time:48 hours
-
Result:Increased the PARP cleavage in both breast cancer cells (MCF7 and MDA-MB-231) and hepatocellular carcinoma cells (Mahlavu).
-
Cell Line:Mahlavu, Huh7, MCF-7 and MDA-MB-231 cancer cells
-
Concentration:5 μM
-
Incubation Time:48 hours
-
Result:Induced cell apoptosis of cancer cells.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:6−8 weeks old male athymic nude mice with hepatocellular carcinoma (Mahlavu cells) and breast (MDA MB-231 cells) xenografts[1]
-
Dosage:40 mg/kg
-
Administration:Oral gavage; 40 mg/kg; twice a week for 4 weeks
-
Result:Significantly reduced the tumor volume following 4 weeks treatment with 40% reductions of tumor volumes in the Mahlavu xenografts. Resulted in about a 50% decreased in tumor volumes as compared to the control group in MDA-MB-231 xenografts. Showed well tolerated in vivo and neither significant bodyweight loss nor toxic effects or mortality were observed.
Chemical Information
-
CAS No. 2750233-50-0
-
Masse moléculaire 374.86
-
Formule C23H19ClN2O
-
SMILES
CC1=CC=CC=C1COC2=CC=C(C3=CC=NN3C4=CC=C(Cl)C=C4)C=C2
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Antitumor agent-79 Related Classifications
HY-151618 Related Classifications
Powered by Bioz